BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem Cells

NEW YORK, NY and PETACH TIKVAH, ISRAEL and KINGSTON, ON, Jun 27, 2014 (Marketwired via COMTEX) BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have reached an important milestone in their technology collaboration, successfully constructing an Alpha prototype of a customized bioreactor for BrainStorm s NurOwn(TM) neurotrophic-factor secreting mesenchymal stem cells. The proprietary bioreactor under development will provide BrainStorm with large-scale manufacturing capabilities, enabling it to achieve economies of scale for its autologous stem cell product. Octane and BrainStorm have successfully developed a sophisticated Alpha prototype of the NurOwn(TM) Bioreactor, utilizing a customized disposable cartridge that is dedicated to the intricacies of BrainStorm s NurOwn(TM) pro
http://bit.ly/1lUMMQI